Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo‐controlled study
Christian J. Hendriksz(Birmingham Children's Hospital), Wolfgang Dummer(BioMarin (United States)), Maurizio Scarpa(Unknown), Hsiang‐Yu Lin(Mackay Memorial Hospital), Peter Slasor(BioMarin (United States)), Vassili Valayannopoulos(Regeneron (United States)), Simon Jones(Manchester University NHS Foundation Trust), Eugen Mengel(University of Hohenheim), Debra L. Lounsbury(BioMarin (United States)), Thomas R. Fleming(University of Washington), Roberto Giugliani(Universidade Federal do Rio Grande do Sul), Paul Harmatz(Unknown), Barbara K. Burton(Women & Children's Hospital of Buffalo), Derralynn Hughes(Royal Free London NHS Foundation Trust)
Cited by 211
Related Papers
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Phenylalanine hydroxylase deficiency: diagnosis and management guideline
|Genetics in Medicine|2014|718
Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia
|Orphanet Journal of Rare Diseases|2014|713
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522